Paper Details

  1. Home
  2. Paper Details

Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.

Author: AriharaZenei, NiitsumaSatsuki, SakuraiKanako, SatoRyota, TakahashiKazuhiro, YauraKazuma

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Immune checkpoint inhibitor (ICI) therapy can cause delayed immune-related adverse events (irAEs), including type 1 diabetes mellitus (DM). This case report describes a patient who developed fulminant type 1 DM six months after discontinuing ICI therapy. This case highlights the importance of regular monitoring for delayed irAEs after ICI therapy.
Paper Details　
Original Abstract of the Article :
The cytotoxic T-lymphocyte antigen-4 and programmed cell death 1 pathways are novel therapeutic targets in immune checkpoint inhibitor (ICI) therapy for cancer. However, they may cause endocrine-related adverse events, including hypophysitis, autoimmune thyroiditis and type 1 diabetes mellitus (DM)....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1620/tjem.254.253

データ提供：米国国立医学図書館（NLM）

The Desert of Immune Checkpoint Inhibitor Therapy: A Case of Fulminant Type 1 Diabetes

Immune checkpoint inhibitor (ICI) therapy has emerged as a powerful weapon in the fight against cancer, but it can also have unexpected side effects. This study takes us on a journey through the desert of ICI therapy, where we encounter a rare case of fulminant type 1 diabetes mellitus (DM) developing after discontinuation of ICI combination therapy. This case report emphasizes the need for vigilant monitoring for delayed immune-related adverse events (irAEs), even after discontinuation of ICI therapy.

Delayed IrAEs: A Silent Threat in the Desert of ICI Therapy

This case report serves as a stark reminder of the potential for delayed irAEs after ICI therapy. The development of fulminant type 1 DM half a year after discontinuation of ICI therapy highlights the need for long-term monitoring and proactive management of potential complications.

Navigating the Desert of ICI Therapy: A Compass for Patient Care

The study underscores the importance of comprehensive patient care in ICI therapy. This case report emphasizes the need for vigilant monitoring for irAEs, both immediate and delayed. Healthcare providers must remain vigilant in their care of patients receiving ICI therapy, ensuring their safety and well-being.

Dr. Camel's Conclusion

This case report highlights the potential for delayed irAEs after ICI therapy. The development of fulminant type 1 DM in this patient underscores the importance of vigilant monitoring for irAEs. This research serves as a reminder of the complex nature of ICI therapy and the importance of comprehensive patient care.

Date :
  1. Date Completed 2022-01-17
  2. Date Revised 2022-01-17
Further Info :

Pubmed ID

34373422

DOI: Digital Object Identifier

10.1620/tjem.254.253

Related Literature

Article Analysis
・Effects of ipilimumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.